Titre : Hyperthermie provoquée

Hyperthermie provoquée : Questions médicales fréquentes

Termes MeSH sélectionnés :

Hyperphosphatemia
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hyperthermie provoquée : Questions médicales les plus fréquentes", "headline": "Hyperthermie provoquée : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hyperthermie provoquée : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-20", "dateModified": "2025-03-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hyperthermie provoquée" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Thérapeutique", "url": "https://questionsmedicales.fr/mesh/D013812", "about": { "@type": "MedicalCondition", "name": "Thérapeutique", "code": { "@type": "MedicalCode", "code": "D013812", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E02" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Psammothérapie", "alternateName": "Ammotherapy", "url": "https://questionsmedicales.fr/mesh/D000646", "about": { "@type": "MedicalCondition", "name": "Psammothérapie", "code": { "@type": "MedicalCode", "code": "D000646", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E02.565.020" } } }, { "@type": "MedicalWebPage", "name": "Diathermie", "alternateName": "Diathermy", "url": "https://questionsmedicales.fr/mesh/D003972", "about": { "@type": "MedicalCondition", "name": "Diathermie", "code": { "@type": "MedicalCode", "code": "D003972", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E02.565.280" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ultrasonothérapie", "alternateName": "Ultrasonic Therapy", "url": "https://questionsmedicales.fr/mesh/D014464", "about": { "@type": "MedicalCondition", "name": "Ultrasonothérapie", "code": { "@type": "MedicalCode", "code": "D014464", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E02.565.280.945" } } } ] }, { "@type": "MedicalWebPage", "name": "Chimiothérapie hyperthermique intrapéritonéale", "alternateName": "Hyperthermic Intraperitoneal Chemotherapy", "url": "https://questionsmedicales.fr/mesh/D000084262", "about": { "@type": "MedicalCondition", "name": "Chimiothérapie hyperthermique intrapéritonéale", "code": { "@type": "MedicalCode", "code": "D000084262", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E02.565.370" } } }, { "@type": "MedicalWebPage", "name": "Bain de vapeur", "alternateName": "Steam Bath", "url": "https://questionsmedicales.fr/mesh/D029002", "about": { "@type": "MedicalCondition", "name": "Bain de vapeur", "code": { "@type": "MedicalCode", "code": "D029002", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E02.565.640" } } } ], "about": { "@type": "MedicalCondition", "name": "Hyperthermie provoquée", "alternateName": "Hyperthermia, Induced", "code": { "@type": "MedicalCode", "code": "D006979", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mohammad-Amin Abdollahifar", "url": "https://questionsmedicales.fr/author/Mohammad-Amin%20Abdollahifar", "affiliation": { "@type": "Organization", "name": "Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: abdollahima@sbmu.ac.ir." } }, { "@type": "Person", "name": "Abbas Aliaghaei", "url": "https://questionsmedicales.fr/author/Abbas%20Aliaghaei", "affiliation": { "@type": "Organization", "name": "Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Jon E Sprague", "url": "https://questionsmedicales.fr/author/Jon%20E%20Sprague", "affiliation": { "@type": "Organization", "name": "The Ohio Attorney General's Center for the Future of Forensic Science, USA. Electronic address: jesprag@bgsu.edu." } }, { "@type": "Person", "name": "Amir Raoofi", "url": "https://questionsmedicales.fr/author/Amir%20Raoofi", "affiliation": { "@type": "Organization", "name": "Leishmaniasis Research Center, Department of Anatomy, Sabzevar University of Medical Sciences, Sabzevar, Iran." } }, { "@type": "Person", "name": "Shabnam Abdi", "url": "https://questionsmedicales.fr/author/Shabnam%20Abdi", "affiliation": { "@type": "Organization", "name": "Department of Anatomical Sciences & Cognitive Neuroscience, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.", "datePublished": "2023-11-01", "url": "https://questionsmedicales.fr/article/37910313", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10157-023-02406-1" } }, { "@type": "ScholarlyArticle", "name": "Phosphorus balance calculator: an individualized tool for treatment of hyperphosphatemia in hemodialysis patients.", "datePublished": "2023-11-30", "url": "https://questionsmedicales.fr/article/38037501", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/ndt/gfad256" } }, { "@type": "ScholarlyArticle", "name": "Hyperphosphatemia and Outcomes in Critically Ill Patients: A Systematic Review and Meta-Analysis.", "datePublished": "2022-05-17", "url": "https://questionsmedicales.fr/article/35665344", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fmed.2022.870637" } }, { "@type": "ScholarlyArticle", "name": "Three Siblings With a Rare Familial Hyperphosphatemia Syndrome: A Case Series.", "datePublished": "2024-03-05", "url": "https://questionsmedicales.fr/article/38576700", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7759/cureus.55575" } }, { "@type": "ScholarlyArticle", "name": "Familial tumoral calcinosis: a rare autosomal recessive disease.", "datePublished": "2024-10-11", "url": "https://questionsmedicales.fr/article/39395830", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bcr-2023-259455" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Thérapeutique", "item": "https://questionsmedicales.fr/mesh/D013812" }, { "@type": "ListItem", "position": 3, "name": "Hyperthermie provoquée", "item": "https://questionsmedicales.fr/mesh/D006979" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hyperthermie provoquée - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hyperthermie provoquée", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hyperthermie provoquée", "description": "Comment diagnostiquer l'hyperthermie provoquée ?\nQuels tests sont utilisés pour confirmer l'hyperthermie ?\nQuels signes cliniques indiquent une hyperthermie ?\nL'hyperthermie est-elle toujours dangereuse ?\nComment différencier l'hyperthermie de la fièvre ?", "url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hyperthermie provoquée", "description": "Quels sont les symptômes de l'hyperthermie provoquée ?\nL'hyperthermie provoquée cause-t-elle des douleurs ?\nPeut-on avoir des troubles de la conscience ?\nY a-t-il des signes cutanés associés ?\nL'hyperthermie provoquée affecte-t-elle la respiration ?", "url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hyperthermie provoquée", "description": "Comment prévenir l'hyperthermie provoquée ?\nLes vêtements influencent-ils l'hyperthermie ?\nFaut-il surveiller la température corporelle ?\nLes pauses sont-elles importantes ?\nL'alimentation joue-t-elle un rôle ?", "url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hyperthermie provoquée", "description": "Comment traiter l'hyperthermie provoquée ?\nDes médicaments sont-ils nécessaires ?\nQuelle est l'importance de l'hydratation ?\nQuand faut-il consulter un médecin ?\nLe repos est-il recommandé ?", "url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hyperthermie provoquée", "description": "Quelles complications peuvent survenir ?\nL'hyperthermie peut-elle être mortelle ?\nQuels organes sont les plus affectés ?\nDes séquelles peuvent-elles persister ?\nComment éviter les complications graves ?", "url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hyperthermie provoquée", "description": "Qui est le plus à risque d'hyperthermie ?\nL'exercice augmente-t-il le risque ?\nLes médicaments influencent-ils le risque ?\nL'humidité joue-t-elle un rôle ?\nLe surpoids est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D006979?mesh_terms=Hyperphosphatemia&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'hyperthermie provoquée ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'évaluation clinique et la mesure de la température corporelle." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer l'hyperthermie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des évaluations physiologiques peuvent être réalisés." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une hyperthermie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent une température élevée, des frissons et une confusion mentale." } }, { "@type": "Question", "name": "L'hyperthermie est-elle toujours dangereuse ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, elle peut être contrôlée, mais nécessite une surveillance." } }, { "@type": "Question", "name": "Comment différencier l'hyperthermie de la fièvre ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'hyperthermie est causée par des facteurs externes, alors que la fièvre est une réponse immunitaire." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'hyperthermie provoquée ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des nausées, des vertiges, des maux de tête et une confusion." } }, { "@type": "Question", "name": "L'hyperthermie provoquée cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des douleurs musculaires et des crampes." } }, { "@type": "Question", "name": "Peut-on avoir des troubles de la conscience ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles de la conscience peuvent survenir en cas d'hyperthermie sévère." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des rougeurs ou des éruptions cutanées peuvent apparaître en cas d'hyperthermie." } }, { "@type": "Question", "name": "L'hyperthermie provoquée affecte-t-elle la respiration ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner une respiration rapide et superficielle." } }, { "@type": "Question", "name": "Comment prévenir l'hyperthermie provoquée ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Évitez les environnements chauds et hydratez-vous régulièrement lors d'activités physiques." } }, { "@type": "Question", "name": "Les vêtements influencent-ils l'hyperthermie ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, porter des vêtements légers et respirants aide à prévenir l'hyperthermie." } }, { "@type": "Question", "name": "Faut-il surveiller la température corporelle ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, surveiller la température est essentiel lors d'activités à risque." } }, { "@type": "Question", "name": "Les pauses sont-elles importantes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, prendre des pauses régulières lors d'activités physiques intenses est crucial." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée aide à maintenir une bonne régulation thermique." } }, { "@type": "Question", "name": "Comment traiter l'hyperthermie provoquée ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut le refroidissement du corps et l'hydratation adéquate." } }, { "@type": "Question", "name": "Des médicaments sont-ils nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être administrés pour soulager les symptômes associés." } }, { "@type": "Question", "name": "Quelle est l'importance de l'hydratation ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'hydratation est cruciale pour prévenir des complications graves liées à l'hyperthermie." } }, { "@type": "Question", "name": "Quand faut-il consulter un médecin ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Consultez un médecin si les symptômes persistent ou s'aggravent malgré le traitement." } }, { "@type": "Question", "name": "Le repos est-il recommandé ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le repos est essentiel pour permettre au corps de récupérer." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des coups de chaleur, des défaillances organiques et des convulsions." } }, { "@type": "Question", "name": "L'hyperthermie peut-elle être mortelle ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une hyperthermie sévère non traitée peut entraîner la mort." } }, { "@type": "Question", "name": "Quels organes sont les plus affectés ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Le cerveau, le cœur et les reins sont particulièrement vulnérables à l'hyperthermie." } }, { "@type": "Question", "name": "Des séquelles peuvent-elles persister ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des séquelles neurologiques peuvent persister après une hyperthermie sévère." } }, { "@type": "Question", "name": "Comment éviter les complications graves ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement rapide et approprié est essentiel pour éviter les complications graves." } }, { "@type": "Question", "name": "Qui est le plus à risque d'hyperthermie ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées, les enfants et celles avec des maladies chroniques sont plus à risque." } }, { "@type": "Question", "name": "L'exercice augmente-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice intense dans des environnements chauds augmente le risque d'hyperthermie." } }, { "@type": "Question", "name": "Les médicaments influencent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent altérer la régulation thermique et augmenter le risque." } }, { "@type": "Question", "name": "L'humidité joue-t-elle un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une humidité élevée augmente le risque d'hyperthermie en réduisant l'évaporation de la sueur." } }, { "@type": "Question", "name": "Le surpoids est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le surpoids peut augmenter le risque d'hyperthermie en réduisant l'efficacité de la thermorégulation." } } ] } ] }

Sources (91 au total)

Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.

Tenapanor is a novel selective inhibitor of intestinal sodium/hydrogen exchanger 3 transporter. This is the first trial to assess the efficacy and safety of tenapanor in Japanese patients with hyperph... This phase 3, open-label, multicenter, single-arm clinical trial targeted patients whose serum phosphorus was within 3.5-7.0 mg/dL with phosphate binders at screening. After phosphate binder washout, ... Of the 54 patients enrolled, 34 completed the study. At week 8, the primary endpoint, mean change in serum phosphorus level (last observation carried forward), was - 1.18 mg/dL (95% confidence interva... Administration of tenapanor resulted in a sufficient reduction in serum phosphorus level at week 8 and was considered safe and tolerable.... NCT04766385....

Phosphorus balance calculator: an individualized tool for treatment of hyperphosphatemia in hemodialysis patients.

Lack of evaluations of the dietary phosphorus and dialysis phosphorus removal in daily clinical practice are the common obstacle to assess phosphorus balance and control phosphorus in hemodialysis pat... A randomized, open-label, multicenter, 4-week clinical trial was conducted. 119 maintenance hemodialysis patients aged 18 to 85 years old and with serum phosphorus level higher than 1.45mmol/l from 3 ... Among 119 randomized participants (mean age, 62 years; 68 male[57%]), 116 completed the trial. By using the phosphorus balance calculator, the individualized group achieved a better phosphorus balance... Phosphorus balance calculator was proved to improve serum phosphorus control in patients undergoing maintenance hemodialysis, offering a new tool for managing hyperphosphatemia....

Hyperphosphatemia and Outcomes in Critically Ill Patients: A Systematic Review and Meta-Analysis.

Serum phosphate level is often deranged during critical illness. Hyperphosphatemia, as a marker of disease severity, attracts more and more attention. This study aimed to evaluate the impact of hyperp... We searched for relevant studies in PubMed, EMBASE, and the Cochrane database up to Jan 10, 2022. Two authors independently screened studies, extracted data, and assessed the study quality. Meta-analy... Ten studies with 60,358 patients met the inclusion criteria. These studies were moderate to high quality. The median prevalence of hyperphosphatemia was 30% (range from 5.6 to 45%). Patients with hype... Our results indicated that hyperphosphatemia was associated with all-cause mortality in critically ill patients. However, due to the retrospective design of the included studies, more prospective, wel... [https://doi.org/10.37766/inplasy2021.12.0130], identifier [INPLASY2021120130]....

Real-World Phosphate Binder Use among Dialysis-Dependent Patients with CKD.

For patients with chronic kidney disease (CKD), the need for phosphate binder (PB) treatment peaks at onset of dialysis. This real-world study assessed rates of PB utilization and switching in patient... We identified patients with PB utilization among those with prevalent DD-CKD using 2018-2019 Medicare Parts A/B/D data. Patients were assigned to cohorts based on primary (most frequently used) PB amo... We identified 136,912 patients with PB use. Proportion of patients adherent ranged from 63.8% (lanthanum carbonate) to 67.7% (sevelamer) and persistent from 85.1% (calcium acetate) to 89.5% (ferric ci... Adherence and persistence rates were low with slight variation across PBs. Net positive switching occurred for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate. Further studies are ne...

Etiology, Comorbidities, and Rate of Progression of Pediatric Chronic Kidney Disease: A Cohort Study.

To evaluate the etiology of pediatric chronic kidney disease (CKD), assess comorbidities, and identify rate of progression of CKD and its risk factors.... Children aged 2-18 y with the Kidney Disease Improving Global Outcome (KDIGO) CKD stages 2-4 were enrolled. The etiology of CKD and its comorbidities were recorded. Kaplan-Meier survival curves were u... Of the 131 patients enrolled, CKD stages 2, 3a, 3b, and 4 constituted 62 (47.3%), 17 (13%), 26 (19.8%), and 26 (19.8%), respectively. At the last follow-up [at median (IQR) 24 (12, 30) mo], the number... Even the earlier stages of CKD had significant comorbidities. The median decline in eGFR was 3.3 mL/min/1.73 m...

The effect of egg white diet on phosphorus control in dialysis patients.

Nutritional interventions have been envisaged to improve hyperphosphatemia and malnutrition, two important risk factors associated with mortality in dialysis patients. We evaluated the effects of egg ... In an open-label, per protocol clinical trial, conducted in Kerman dialysis centers, 150 hemodialysis patients aged ≥18 years with serum phosphorus ≥5.5 mg/dl were included in the study. All participa... At the baseline, there were no significant differences in the laboratory variables between the two groups. After 8 weeks, serum cholesterol (124.3 ± 38.1, vs. 135.8 ± 28.8, p = 0.003) and phosphorus l... The results showed that the egg white could be a useful source of protein for dialysis patients, as it simultaneously reduces serum phosphorus and cholesterol, and increases serum albumin....

Pseudohypoparathyroidism: a diagnosis to consider once a PTH elevation is detected.

Pseudohypoparathyroidism (PHP) is a rare disease, which can occur in the youth, characterized by hypocalcemia and hyperphosphatemia due to resistance to parathyroid hormone (PTH) in target organs. Thi... Herein we report the clinical history of a boy with PHP1B with an interesting clinical presentation. He came in fact to the attention of the Emergency Department because of a spontaneously resolving e... The simultaneous presence of symptomatic acute hypocalcemia and long QT syndrome undoubtedly required particular attention both in the management of the onset and in the more in-depth subsequent diagn...